Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Jun 2010
Randomized Controlled TrialEDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
Hereditary angioedema (HAE) is a genetic disorder resulting from low levels of C1-inhibitor activity that manifests as acute attacks of variable and sometimes life-threatening edema. Ecallantide is a novel potent inhibitor of human plasma kallikrein, a key mediator of the excessive formation of bradykinin associated with the signs and symptoms of an HAE attack. ⋯ Ecallantide appears to be an effective and safe treatment for acute attacks of HAE.
-
Ann. Allergy Asthma Immunol. · Jun 2010
Asthma control and activity limitations: insights from the Real-world Evaluation of Asthma Control and Treatment (REACT) study.
Uncontrolled asthma remains prevalent in the United States and confers a substantial burden on the health care system. ⋯ Compared with patients with controlled asthma, those with uncontrolled asthma are at higher risk for limitations in outdoor activity, physical activity, and daily activity. To help patients achieve optimal health, asthma management should include routine assessment of activity limitations and assessment and coordinated care for comorbid conditions.